Alx Oncology Holdings Inc (ALXO) Stock Price, Quote & News

Company Profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 466 7125

Website: www.alxoncology.com

Address:

323 Allerton Avenue, South San Francisco, United States

maplelakeduckslayer Jan. 14 at 8:56 PM

$ALXO this is your dip buy if you missed 1.10 area. Moving avgs on the daily will provide support

0 · Reply

StarLord13 Jan. 14 at 5:39 PM

$ALXO Can make a living selling this thing at $1.50 and re-buying near a dollar every time.

0 · Reply

StarLord13 Jan. 13 at 8:19 PM

$ALXO They will deliver their corporate presentation Thursday, Jan 15th at JP Morgan Conference at 12pm pacific time.

1 · Reply

MakingMoneyHere Jan. 13 at 8:10 PM

$ALXO With an average antitumor activity of 70, 80% that EVORPACEPT shows, I expect that with the first results of ASPEN-CRC they will increase the share by at least 200%. They have come a long way, they have a fairly large selection of candidates that have increased expression of CD-47, so I think that CRC will be between 80 and 90% ORR...

0 · Reply

StarLord13 Jan. 13 at 4:59 PM

$ALXO This stock is always either falling off a cliff or blasting into orbit 😂

0 · Reply

Bullisch_150 Jan. 13 at 4:56 PM

$ALXO Wow nice big buyer

1 · Reply

Bullisch_150 Jan. 13 at 4:14 PM

$ALXO Mega buyout

1 · Reply

Bullisch_150 Jan. 12 at 6:33 PM

$ALXO monsterstock is coming! cancer fight biotech

0 · Reply

P119 Jan. 9 at 1:09 AM

$ALXO something is smoking here….

0 · Reply

JohnTrack Jan. 8 at 5:38 PM

$ALXO on watchlist, sipping coffee...

0 · Reply

ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 8:30 AM EST - 6 days ago

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

Dec 7, 2025, 8:00 AM EST - 5 weeks ago

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

Nov 18, 2025, 11:00 AM EST - 2 months ago

ALX Oncology to Present at Upcoming Investor Conferences

Nov 7, 2025, 3:56 PM EST - 2 months ago

ALX Oncology Holdings Inc. (ALXO) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 8:15 AM EST - 2 months ago

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 30, 2025, 8:30 AM EDT - 2 months ago

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

Oct 23, 2025, 12:30 PM EDT - 2 months ago

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

Oct 3, 2025, 9:05 AM EDT - 3 months ago

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 12, 2025, 8:30 AM EDT - 4 months ago

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

Aug 29, 2025, 12:00 PM EDT - 4 months ago

ALX Oncology to Participate in Upcoming Investor Conferences in September

Aug 19, 2025, 8:00 AM EDT - 5 months ago

ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors

Aug 12, 2025, 9:45 PM EDT - 5 months ago

ALX Oncology Holdings Inc. (ALXO) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 5 months ago

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 5, 2025, 8:00 AM EDT - 5 months ago

ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025

May 30, 2025, 8:00 AM EDT - 8 months ago

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

May 20, 2025, 8:00 AM EDT - 8 months ago

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

May 13, 2025, 8:00 AM EDT - 8 months ago

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

May 8, 2025, 8:30 AM EDT - 8 months ago

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 2, 2025, 8:00 AM EDT - 9 months ago

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 25, 2025, 1:10 PM EDT - 9 months ago

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

Apr 25, 2025, 9:00 AM EDT - 9 months ago

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

Mar 6, 2025, 4:01 PM EST - 11 months ago

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 5, 2025, 8:00 AM EST - 11 months ago

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

Feb 27, 2025, 8:00 AM EST - 11 months ago

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 18, 2025, 8:00 AM EST - 11 months ago

ALX Oncology to Host Virtual R&D Day on March 5, 2025

Jan 23, 2025, 8:00 AM EST - 1 year ago

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

Jan 22, 2025, 4:01 PM EST - 1 year ago

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

Jan 21, 2025, 5:00 PM EST - 1 year ago

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

Dec 18, 2024, 8:00 AM EST - 1 year ago

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

Nov 14, 2024, 8:00 AM EST - 1 year ago

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

Nov 7, 2024, 4:00 PM EST - 1 year ago

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 1, 2024, 5:30 PM EDT - 1 year ago

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

Sep 11, 2024, 10:36 PM EDT - 1 year ago

ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations

Aug 6, 2024, 4:01 PM EDT - 1 year ago

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

Jul 31, 2024, 4:01 PM EDT - 1 year ago

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

Jul 31, 2024, 5:30 AM EDT - 1 year ago

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Jun 27, 2024, 4:13 AM EDT - 1 year ago

ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation

Jun 2, 2024, 10:00 AM EDT - 1 year ago

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

May 29, 2024, 9:00 AM EDT - 1 year ago

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

May 9, 2024, 4:00 PM EDT - 1 year ago

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 9:00 AM EDT - 1 year ago

ALX Oncology Appoints Allison Dillon as Chief Business Officer

Apr 24, 2024, 10:00 AM EDT - 1 year ago

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

$ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)$

Apr 9, 2024, 5:30 PM EDT - 1 year ago

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)

Mar 7, 2024, 4:03 PM EST - 2 years ago

ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 5, 2024, 4:30 PM EST - 2 years ago

ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting

Dec 8, 2023, 8:30 AM EST - 2 years ago

ALX Oncology shares jump 9% after Jefferies upgrade

Nov 13, 2023, 4:05 PM EST - 2 years ago

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 10, 2023, 4:05 PM EDT - 2 years ago

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 9, 2023, 12:38 AM EDT - 2 years ago

ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept

maplelakeduckslayer Jan. 14 at 8:56 PM

$ALXO this is your dip buy if you missed 1.10 area. Moving avgs on the daily will provide support

0 · Reply

StarLord13 Jan. 14 at 5:39 PM

$ALXO Can make a living selling this thing at $1.50 and re-buying near a dollar every time.

0 · Reply

StarLord13 Jan. 13 at 8:19 PM

$ALXO They will deliver their corporate presentation Thursday, Jan 15th at JP Morgan Conference at 12pm pacific time.

1 · Reply

MakingMoneyHere Jan. 13 at 8:10 PM

0 · Reply

StarLord13 Jan. 13 at 4:59 PM

$ALXO This stock is always either falling off a cliff or blasting into orbit 😂

0 · Reply

Bullisch_150 Jan. 13 at 4:56 PM

$ALXO Wow nice big buyer

1 · Reply

Bullisch_150 Jan. 13 at 4:14 PM

$ALXO Mega buyout

1 · Reply

Bullisch_150 Jan. 12 at 6:33 PM

$ALXO monsterstock is coming! cancer fight biotech

0 · Reply

P119 Jan. 9 at 1:09 AM

$ALXO something is smoking here….

0 · Reply

JohnTrack Jan. 8 at 5:38 PM

$ALXO on watchlist, sipping coffee...

0 · Reply

JohnTrack Jan. 8 at 4:21 PM

$ALXO wire pickup on this name https://www.rapidticker.com/news/alxo-alx-oncology-to-present-at-2427d7

0 · Reply

MakingMoneyHere Jan. 8 at 1:46 PM

$ALXO https://www.stocktitan.net/news/ALXO/alx-oncology-advances-separate-clinical-trials-evaluating-asrpc6jteeii.html

0 · Reply

StarLord13 Jan. 6 at 9:42 PM

$ALXO I guess there is no bounce 🤷‍♂️ Heading straight for penny land.

1 · Reply

superyin Jan. 6 at 4:41 PM

$TLRY people are moving into silver and precious metals and tech, presumably—Tilray moves more like a pharma ticker ($ALXO showed similar charts summer-winter last year), underperforming the market most days but moving up on volatility and news even on market down days

1 · Reply

maplelakeduckslayer Jan. 5 at 6:57 PM

$ALXO

0 · Reply

P119 Jan. 1 at 9:00 PM

$ALXO $SPY $QQQ Wish you a very happy new year 🎊

0 · Reply

P119 Dec. 31 at 3:34 PM

$ALXO tax sellers.. not worried

0 · Reply

BillionerOfKing Dec. 29 at 4:45 PM

$ALXO Current Stock Price: $1.29 Contracts to trade: $0.5 ALXO Jan 16 2026 Call Entry: $0.30 Exit: $0.47 ROI: 55% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

SuperGreenToday Dec. 26 at 10:16 PM

$ALXO

0 · Reply

StarLord13 Dec. 26 at 7:11 PM

$ALXO If it breaks $1.25 it’s going under a dollar.

1 · Reply

SystematicSage Dec. 26 at 6:36 AM

$ALXO Investors are watching management behavior more closely than guidance language. Strategic direction should avoid unnecessary detours. Capital misallocation remains the key downside risk. Future returns will be dictated by execution quality, not headlines.

0 · Reply

HerdingBehavior Dec. 25 at 3:51 PM

$ALXO Investors are recalibrating expectations as the balance shifts from vision to execution. Cost discipline must coexist with targeted investment. Evidence of resilience during turbulence would be constructive. Success from here is primarily about discipline, not discovery.

0 · Reply

Market Cap	78.07M
Revenue (ttm)	0.00
Net Income (ttm)	-134.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.23

Volume	281,700
Avg Vol	260,958
Day's Range	N/A - N/A
Shares Out	54.22M
Stochastic %K	86%
Beta	0.51
Analysts	Strong Sell
Price Target	$3.00